Toutes les photos(1)

Documents

COO/COA

Y0001257

Levetiracetam impurity D

Name: Levetiracetam impurity D
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(2R)-2-(2-Oxopyrrolidin-1-yl)butanamide, (R)-Etiracetam

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₈H₁₄N₂O₂

Numéro CAS:

103765-01-1

Poids moléculaire :

170.21

Code UNSPSC :

41116107

Nomenclature NACRES :

NA.24

Qualité

pharmaceutical primary standard

Famille d'API

levetiracetam

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1

Clé InChI

HPHUVLMMVZITSG-ZCFIWIBFSA-N

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

Mention d'avertissement

Warning

Mentions de danger

H302,H319,H411

Conseils de prudence

P264 - P270 - P273 - P280 - P301 + P312 - P305 + P351 + P338

Classification des risques

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Supelco

PHR1447

Levetiracetam

[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].

S Yamashita et al.

No to hattatsu = Brain and development, 45(1), 64-66 (2013-04-19)

[Dynamics of cognitive and emotional-volitional disorders in children and adolescents with refractory epilepsy during the treatment with levetiracetam].

Iu V Popov et al.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(5 Pt 2), 48-52 (2013-06-07)

We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders

Asymptomatic elevation of liver enzymes due to levetiracetam: a case report.

Nitin K Sethi et al.

Drug metabolism and drug interactions, 28(2), 123-124 (2013-02-20)

Levetiracetam is a commonly used broad-spectrum anticonvulsant efficacious in both partial and generalized seizures. It has an extremely favorable side effect profile with few drug-drug interactions, low potential for hematological and hepatic toxicity, and thus has rapidly become the preferred

Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet.

Mika H Martikainen et al.

Epileptic disorders : international epilepsy journal with videotape, 14(4), 438-441 (2012-12-19)

Epilepsy is a common manifestation of mitochondrial disease associated with mutations of the mitochondrial polymerase γ (POLG). Prognosis of mitochondrial epilepsy is often poor and there are few reports of successful treatment of POLG-related epilepsy. We describe a 26-year-old woman

Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behavior before and after treatment with levetiracetam.

Helge Bjørnæs et al.

Epilepsy & behavior : E&B, 27(1), 40-48 (2013-02-05)

We performed a double-blind placebo-controlled crossover study of the effects of spike activity during sleep and when awake on learning, long-term memory, vigilance and behavior before and after treatment with levetiracetam in children with electrical status epilepticus during sleep. At

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique